Disease-modifying therapies (DMT) administered to patients with multiple sclerosis (MS) can influence immune responses to SARS-CoV-2 and vaccine efficacy. However, data on the detailed phenotypic, functional and metabolic characteristics of antigen (Ag)-specific cells following the third dose of mRNA vaccine remain scarce. Here, using flow cytometry and 45-parameter mass cytometry, we broadly investigate the phenotype, function and the single-cell metabolic profile of SARS-CoV-2-specific T and B cells up to 8 months after the third dose of mRNA vaccine in a cohort of 94 patients with MS treated with different DMT, including cladribine, dimethyl fumarate, fingolimod, interferon, natalizumab, teriflunomide, rituximab or ocrelizumab. Almost all patients display functional immune response to SARS-CoV-2. Different metabolic profiles characterize antigen-specific-T and -B cell response in fingolimod- and natalizumab-treated patients, whose immune response differs from all the other MS treatments.

Disease-modifying therapies (DMT) administered to patients with multiple sclerosis (MS) can influence immune responses to SARS-CoV-2 and vaccine efficacy. However, data on the detailed phenotypic, functional and metabolic characteristics of antigen (Ag)-specific cells following the third dose of mRNA vaccine remain scarce. Here, using flow cytometry and 45-parameter mass cytometry, we broadly investigate the phenotype, function and the single-cell metabolic profile of SARS-CoV-2-specific T and B cells up to 8 months after the third dose of mRNA vaccine in a cohort of 94 patients with MS treated with different DMT, including cladribine, dimethyl fumarate, fingolimod, interferon, natalizumab, teriflunomide, rituximab or ocrelizumab. Almost all patients display functional immune response to SARS-CoV-2. Different metabolic profiles characterize antigen-specific-T and -B cell response in fingolimod- and natalizumab-treated patients, whose immune response differs from all the other MS treatments.

Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients / DE BIASI, Sara; LO TARTARO, Domenico; Neroni, Anita; Rau, Moritz; Paschalidis, Nikolaos; Borella, Rebecca; Santacroce, Elena; Paolini, Annamaria; Gibellini, Lara; Ciobanu, ALIN LIVIU; Cuccorese, Michela; Trenti, Tommaso; Rubio, Ignacio; Vitetta, Francesca; Cardi, Martina; José Argüello, Rafael; Ferraro, Diana; Cossarizza, Andrea. - In: NATURE COMMUNICATIONS. - ISSN 2041-1723. - 15:1(2024). [10.1038/s41467-024-47013-0]

Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients

Sara De Biasi
;
Domenico Lo Tartaro;Anita Neroni;Rebecca Borella;Elena Santacroce;Annamaria Paolini;Lara Gibellini;Alin Liviu Ciobanu;Martina Cardi;Diana Ferraro;Andrea Cossarizza
2024

Abstract

Disease-modifying therapies (DMT) administered to patients with multiple sclerosis (MS) can influence immune responses to SARS-CoV-2 and vaccine efficacy. However, data on the detailed phenotypic, functional and metabolic characteristics of antigen (Ag)-specific cells following the third dose of mRNA vaccine remain scarce. Here, using flow cytometry and 45-parameter mass cytometry, we broadly investigate the phenotype, function and the single-cell metabolic profile of SARS-CoV-2-specific T and B cells up to 8 months after the third dose of mRNA vaccine in a cohort of 94 patients with MS treated with different DMT, including cladribine, dimethyl fumarate, fingolimod, interferon, natalizumab, teriflunomide, rituximab or ocrelizumab. Almost all patients display functional immune response to SARS-CoV-2. Different metabolic profiles characterize antigen-specific-T and -B cell response in fingolimod- and natalizumab-treated patients, whose immune response differs from all the other MS treatments.
2024
15
1
Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients / DE BIASI, Sara; LO TARTARO, Domenico; Neroni, Anita; Rau, Moritz; Paschalidis, Nikolaos; Borella, Rebecca; Santacroce, Elena; Paolini, Annamaria; Gibellini, Lara; Ciobanu, ALIN LIVIU; Cuccorese, Michela; Trenti, Tommaso; Rubio, Ignacio; Vitetta, Francesca; Cardi, Martina; José Argüello, Rafael; Ferraro, Diana; Cossarizza, Andrea. - In: NATURE COMMUNICATIONS. - ISSN 2041-1723. - 15:1(2024). [10.1038/s41467-024-47013-0]
DE BIASI, Sara; LO TARTARO, Domenico; Neroni, Anita; Rau, Moritz; Paschalidis, Nikolaos; Borella, Rebecca; Santacroce, Elena; Paolini, Annamaria; Gibe...espandi
File in questo prodotto:
File Dimensione Formato  
2024_De Biasi_NatComms.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 6.03 MB
Formato Adobe PDF
6.03 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1341750
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact